• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Wells Fargo initiated coverage on Arcus Biosciences with a new price target

    10/8/24 7:34:04 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCUS alert in real time by email
    Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00
    Get the next $RCUS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RCUS

    DatePrice TargetRatingAnalyst
    2/26/2025$18.00 → $24.00Neutral → Buy
    H.C. Wainwright
    10/21/2024$20.00Neutral
    H.C. Wainwright
    10/8/2024$29.00Overweight
    Wells Fargo
    11/18/2022$33.00Neutral
    BofA Securities
    10/11/2022$40.00Overweight
    Morgan Stanley
    11/19/2021$42.00 → $53.00Buy
    Citigroup
    11/19/2021$48.00 → $60.00Overweight
    Barclays
    11/18/2021$68.00 → $100.00Outperform
    SVB Leerink
    More analyst ratings

    $RCUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Jarrett Jennifer exercised 50,292 shares at a strike of $1.23 and sold $750,412 worth of shares (50,292 units at $14.92) (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    10/8/25 7:08:18 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Azoy Alexander sold $36,803 worth of shares (2,831 units at $13.00), decreasing direct ownership by 9% to 27,363 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    9/30/25 6:59:03 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Azoy Alexander sold $18,758 worth of shares (1,579 units at $11.88), decreasing direct ownership by 5% to 30,194 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    9/5/25 7:48:11 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    SEC Filings

    View All

    Arcus Biosciences Inc. filed SEC Form 8-K: Other Events

    8-K - Arcus Biosciences, Inc. (0001724521) (Filer)

    10/14/25 9:00:00 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arcus Biosciences Inc.

    144 - Arcus Biosciences, Inc. (0001724521) (Subject)

    10/6/25 4:32:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Inc. filed SEC Form 8-K: Other Events

    8-K - Arcus Biosciences, Inc. (0001724521) (Filer)

    10/6/25 10:02:38 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arcus Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Arcus Biosciences from Neutral to Buy and set a new price target of $24.00 from $18.00 previously

    2/26/25 7:16:55 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Arcus Biosciences with a new price target

    H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00

    10/21/24 7:58:13 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Arcus Biosciences with a new price target

    Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00

    10/8/24 7:34:04 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:06:05 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:05:56 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/20/25 7:42:29 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

    Taiho Pharmaceutical Co., Ltd. ("Taiho") and Arcus Biosciences, Inc. (NYSE:RCUS, "Arcus")) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain other territories in Asia (excluding mainland China). This option exercise is based on a 2017 option and license agreement between Taiho and Arcus. This is the fifth option exercise by Taiho to an Arcus program. In exchange for the exclusive license to casdatifan, Taiho will make an option exercise payment, as well as additional payments upon ach

    10/19/25 7:00:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

    First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing development of domvanalimab plus zimberelimab and chemotherapy in the Phase 3 STAR-221 study in the same patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced the first OS results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced unresectable or metastatic gastric, gastroesophageal

    10/12/25 6:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 60,300 shares of the Company's common stock at an exercise price per share of $15.05, which was the closing price on October 8, 2025, and restricted stock units to acquire a total of 30,150 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January

    10/9/25 4:35:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Financials

    Live finance-specific insights

    View All

    Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

    Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line ccRCC patients, both of which will begin shortly Arcus will host a conference call to discuss these data at 5:0

    6/1/25 10:45:00 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

    Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Additional data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a tyrosine kinase inhibitor (TKI) therapy are expected in the fall Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025 Arcus is well positioned

    5/6/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

    New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The ASCO presentation will include a more mature data cut than that described in the abstract and will include safety and initial efficacy data for the 100mg casdatifan once-daily (QD) plus 60mg cabozantinib QD cohort Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing diff

    4/23/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Leadership Updates

    Live Leadership Updates

    View All

    Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock at an exercise price per share of $12.45, which was the closing price on February 10, 2025, and restricted stock units to acquire a total of 75,193 shares of the Company's common stock. In addition to the awards to Dr. Markus, the Co

    2/11/25 4:35:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

    Dr. Markus will oversee Arcus's clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies   Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsibilities will include oversight of Arcus's clinical development

    1/21/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo

    8/24/22 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

    SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    11/12/24 9:50:12 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

    SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    10/17/24 11:31:06 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care